Stevee Williams, a Houston restaurant manager, found herself grappling with anorexia again as she prepared for her sister’s wedding, a struggle that resurfaced despite her use of GLP-1 weight-loss drugs, according to a report from The Washington Post. Meanwhile, a writer for The Nation detailed a lifelong battle with food, shaped by family dynamics and societal pressures, while The Curvy Fashionista highlighted the resilience of the plus-size market amid GLP-1 drug anxieties. A medical perspective from AOL warned of rising risks for older adults, particularly women, whose eating disorders may go undiagnosed.
Personal Struggles and the GLP-1 Paradox
Williams’ story, recounted in The Washington Post, underscores a growing concern: GLP-1 medications, while effective for weight loss, may trigger or worsen eating disorders. Diagnosed with anorexia at 17, Williams faced renewed anxiety about her appearance, a struggle she described as “never leaving.” Her experience mirrors broader trends, as AOL noted that 13% of women over 50 exhibit disordered eating symptoms, a figure rising amid the popularity of GLP-1s. The 53-year-old patient in AOL’s report exemplifies this risk, admitting she sought the drug “just because it was marketed to me,” highlighting a trend where desire for weight loss becomes a goal in itself.
The Nation article offers a deeply personal lens, with the author reflecting on a lifelong tension between food and restriction. “I’ve been approximately 30 percent fatter than I should have been… since I was 9,” they wrote, tracing their struggles to family attitudes toward weight. Their sister, with 11 percent body fat, faced no such scrutiny, illustrating how societal expectations disproportionately affect individuals. This dynamic, the writer argues, fuels a cycle of “restriction, which begot desire, which begot more restriction,” a pattern that GLP-1s may exacerbate.
The reporting from The Washington Post highlights how these physiological shifts interact with psychological vulnerability. For individuals like Williams, the medication’s ability to suppress appetite creates a physical feedback loop that can mimic the early stages of restrictive eating disorders. Experts interviewed for the report emphasize that the medical community is currently grappling with how to distinguish between successful metabolic management and the onset of clinical disordered eating behaviors.
The Plus-Size Market and Pharmaceutical Pressure
Despite concerns, the plus-size fashion market remains robust, valued at $244.85 billion in 2025 and projected to hit $395.60 billion by 2034, according to The Curvy Fashionista. Yet executives in the industry, as noted in the same article, express anxiety that GLP-1s might “kill” demand. One brand leader, interviewed twice this week, questioned whether the drugs would deter customers, revealing a disconnect between corporate priorities and the community’s needs. “The plus size consumer wanted connection. Community. To be seen,” the writer emphasized, criticizing leaders who fail to grasp this reality.
This tension reflects broader cultural shifts. The Nation writer noted that diet culture has long been intertwined with the plus-size market, yet growth has persisted. “Every magazine cover promising a new body by summer since approximately 1987” has not deterred demand, suggesting that GLP-1s may not be the existential threat some fear. However, the article warns that pharmaceutical marketing—featuring “before-and-after photos” and “dramatic appetite loss as a win”—could normalize harmful behaviors, particularly among older women. The discourse within the industry continues to evolve as brands attempt to balance the realities of shifting consumer health trends with the foundational mission of inclusive fashion.
Medical Warnings and Undiagnosed Risks
Physicians are sounding alarms. A AOL report detailed a 53-year-old patient who sought GLP-1s without clear motivation, prompting concerns about overprescription. The article cited a 2024 study in the International Journal of Eating Disorders linking GLP-1s to exacerbated eating disorders, a finding echoed by The Washington Post’s focus on vulnerable populations. “We’re trained to miss eating disorders in older women,” one physician admitted, noting that symptoms like meal-skipping are often misinterpreted as health management rather than disordered behavior.
The AOL article also highlighted a KFF poll showing 1 in 8 American adults uses GLP-1s, with the 50-64 age group leading. This demographic, already navigating menopause and metabolic shifts, faces unique risks. “The overwhelm alone could trigger disordered eating,” the physician wrote, underscoring the need for tailored care. Yet, as The Nation noted, medical education often overlooks these cases, perpetuating a “classic presentation” of anorexia in young women. This oversight creates a gap in clinical oversight, as older patients may not be screened for the same psychological markers that practitioners look for in younger cohorts.
Furthermore, the reliance on GLP-1s is prompting a re-evaluation of how primary care physicians screen for eating disorders during routine check-ups. Given the increased prevalence of these prescriptions, medical professionals are being urged to implement more rigorous psychological assessments before authorizing long-term use, especially for patients with a documented history of body dysmorphia or restrictive eating patterns.
What’s Next? A Call for Nuanced Understanding
As the usage of GLP-1s continues to expand across diverse age groups, the intersection of pharmaceutical intervention and mental health remains a critical area of concern. Stakeholders, including patient advocacy groups and medical associations, are increasingly calling for more comprehensive guidelines that go beyond simple BMI metrics. The focus is shifting toward a more nuanced understanding of patient history and the psychological impact of rapid weight loss.
For individuals like those featured in these reports, the path forward requires a balance between medical treatment and psychological support. As The Washington Post and other sources suggest, the current climate necessitates that providers remain vigilant about the potential for these drugs to mask underlying mental health struggles. Clinical guidelines and provider training must evolve to address the broader spectrum of patients vulnerable to disordered eating patterns, ensuring that the drive for health improvement does not come at the cost of long-term psychological well-being.
